Indaptus Therapeutics (INDP) Non-Current Assets (2020 - 2025)
Indaptus Therapeutics (INDP) posted quarterly Non-Current Assets of $401059.0 for Q3 2025, down 34.29% year-over-year from $610383.0 in Q3 2024, and down 5.89% quarter-over-quarter from $426149.0 in Q2 2025.
Indaptus Therapeutics (INDP) Non-Current Assets (2020 - 2025) Analysis & Trends
Indaptus Therapeutics' Non-Current Assets history runs 6 years deep, the most recent figure standing at $401059.0 for Q3 2025.
- In Q3 2025, Non-Current Assets fell 34.29% year-over-year to $401059.0; the TTM figure through Sep 2025 stood at $401059.0 (down 34.29% YoY), while the FY2024 annual figure was $720426.0, down 22.42% from the prior year.
- Non-Current Assets for Q3 2025 stood at $401059.0, down from $426149.0 in the prior quarter.
- The five-year high for Non-Current Assets was $5.3 million in Q1 2021, with the low at $4335.0 in Q3 2021.
- The 5-year median for Non-Current Assets is $720426.0 (2024), against an average of $902055.9.
- Peak annual rise in Non-Current Assets reached 19722.88% in 2022, while the deepest fall reached 96.83% in 2022.
- Indaptus Therapeutics' Non-Current Assets stood at $189365.0 in 2021, then surged by 332.8% to $819564.0 in 2022, then grew by 13.31% to $928669.0 in 2023, then declined by 22.42% to $720426.0 in 2024, then tumbled by 44.33% to $401059.0 in 2025.
- Business Quant data shows INDP's Non-Current Assets at $401059.0 in Q3 2025, $426149.0 in Q2 2025, and $450691.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 401,059.00 |
| Jun 30, 2025 | 426,149.00 |
| Mar 31, 2025 | 450,691.00 |
| Dec 31, 2024 | 720,426.00 |
| Sep 30, 2024 | 610,383.00 |
| Jun 30, 2024 | 633,358.00 |
| Mar 31, 2024 | 655,846.00 |
| Dec 31, 2023 | 928,669.00 |
| Sep 30, 2023 | 950,534.00 |
| Jun 30, 2023 | 971,950.00 |
| Mar 31, 2023 | 992,932.00 |
| Dec 31, 2022 | 819,564.00 |
| Sep 30, 2022 | 859,322.00 |
| Jun 30, 2022 | 786,634.00 |
| Mar 31, 2022 | 166,845.00 |
| Dec 31, 2021 | 189,365.00 |
| Sep 30, 2021 | 4,335.00 |
| Jun 30, 2021 | 1.30 Mn |
| Mar 31, 2021 | 5.27 Mn |
| Dec 31, 2020 | 45,794.00 |